Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,156 GBX | -0.12% | +7.88% | +14.68% |
05-02 | AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial | MT |
05-02 | AstraZeneca: research into respiratory diseases | CF |
End-of-day quotes
Sector Other Pharmaceuticals
Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
---|---|---|---|---|---|---|
236B | ||||||
699B | ||||||
571B | ||||||
364B | ||||||
326B | ||||||
286B |
- Stock Market
- Equities
- AZN Stock
- Charts AstraZeneca PLC
- Sector Chart